The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Oral Solid Dosage Contract Manufacturing Global Market Report 2024, the oral solid dosage contract manufacturing market is expected to show promising growth in the forecast period.

The oral solid dosage contract manufacturing market has experienced significant growth in recent years and is poised for further expansion. As of 2023, the market size was valued at $36.70 billion and is expected to reach $39.39 billion by 2024, reflecting a compound annual growth rate (CAGR) of 7.3%. This robust growth is driven by several factors including an increasing global population, the rising prevalence of chronic diseases, and heightened focus on research and development. Looking ahead, the market is projected to grow to $52.94 billion by 2028, maintaining the same CAGR of 7.3%. The future growth can be attributed to increased outsourcing by pharmaceutical companies, advancements in drug delivery technologies, and heightened drug development activities.

Key Drivers of Market Growth

• Outsourcing by Pharmaceutical Companies: Many pharmaceutical companies are increasingly outsourcing their manufacturing processes to focus on core competencies, such as drug discovery and development. This trend is expected to continue, driving demand for oral solid dosage contract manufacturing.
• Advancements in Drug Delivery Technology: Innovations in drug delivery systems, such as controlled-release technologies and 3D printing, are enhancing the efficiency and effectiveness of drug delivery, contributing to market growth.
• Increasing Drug Development Activities: The rise in drug development activities, driven by the need for new and effective treatments, is fueling demand for contract manufacturing services.

Rising Demand for Generic Drugs
The demand for generic drugs is a major factor propelling the growth of the oral solid dosage contract manufacturing market. Generic drugs, which are bioequivalent to brand-name drugs, are increasingly favored due to their cost-effectiveness and patent expirations. This demand is supported by regulatory incentives and expanding healthcare access. For instance, in 2022, the FDA reported that 91% of prescriptions in the USA were filled with generic drugs. The contract manufacturing sector plays a crucial role in producing and distributing these generics by enhancing operational efficiency and reducing costs. This trend is expected to drive market growth as the industry continues to meet the rising demand for affordable medications.

View More On The Oral Solid Dosage Contract Manufacturing Market Report 2024 – https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-contract-manufacturing-global-market-report

Major Companies and Innovations

• Innovative Manufacturing Solutions: Leading companies in the oral solid dosage contract manufacturing market are investing in innovative solutions to maintain competitiveness. For example, WuXi STA, a Chinese pharmaceutical company, launched its first continuous manufacturing line for oral solid products in January 2023. This state-of-the-art facility leverages continuous manufacturing processes to enhance production efficiency, quality, and flexibility.
• Strategic Acquisitions: In August 2022, Catalent Inc. acquired Metrics Contract Services for $475 million, aiming to boost its capabilities in oral solid dosage forms. This acquisition highlights the trend of strategic expansions to enhance manufacturing capabilities and meet the growing demand.

Market Segmentation
The oral solid dosage contract manufacturing market is segmented into various categories:

1. By Product Type: Includes tablets, capsules, powders, granules, and other types.
2. By Service: Encompasses drug product development, fill-finish product manufacturing, API manufacturing, packaging and labeling, among others.
3. By Therapeutic Area: Covers oncology, cardiovascular diseases, metabolic disorders, neurological disorders, infectious diseases, gastrointestinal diseases, and other areas.
4. By End User: Differentiates between large companies and medium/small-sized companies.

Regional Insights
Asia-Pacific was the largest region in the oral solid dosage contract manufacturing market in 2023. The region’s growth is driven by its expanding pharmaceutical industry and increasing outsourcing trends.

In conclusion, the oral solid dosage contract manufacturing market is on a strong growth trajectory, fueled by rising demand for generic drugs, technological advancements, and strategic industry developments. As pharmaceutical companies continue to seek efficient and cost-effective manufacturing solutions, the market is set to expand further in the coming years.

Request A Sample Of The Global Oral Solid Dosage Contract Manufacturing Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=16137&type=smp